Stock Scorecard

Stock Summary for Marker Therapeutics Inc (MRKR) - $0.87 as of 9/4/2025 5:05:37 AM EST

Total Score

8 out of 30

Safety Score

22 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for MRKR

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for MRKR

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for MRKR

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for MRKR

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for MRKR (22 out of 100)

Stock Price Rating (Max of 10) 1
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 6
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 6
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for MRKR

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference - Marker Therapeutics ( NASDAQ:MRKR ) 8/28/2025 12:00:00 PM
Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference 8/28/2025 12:00:00 PM
Marker Therapeutics Stock Drops After Report About Lymphoma Treatment - Marker Therapeutics ( NASDAQ:MRKR ) 8/26/2025 4:34:00 PM
Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma 8/26/2025 11:00:00 AM
Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference - Marker Therapeutics ( NASDAQ:MRKR ) 7/30/2025 12:00:00 PM
Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference 7/30/2025 12:00:00 PM
Dow Jumps Over 100 Points; PepsiCo Posts Upbeat Earnings - GameSquare Holdings ( NASDAQ:GAME ) , CareDx ( NASDAQ:CDNA ) 7/17/2025 2:12:00 PM
Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma - Marker Therapeutics ( NASDAQ:MRKR ) 6/17/2025 12:00:00 PM
Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma 6/17/2025 12:00:00 PM
Marker Therapeutics to Spotlight Multi-Antigen Recognizing ( MAR ) -T Cells in High-Profile Panel on CAR-T Cell Therapies 5/19/2025 12:00:00 PM

Financial Details for MRKR

Company Overview
Ticker MRKR
Company Name Marker Therapeutics Inc
Country USA
Description Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based immunotherapies and peptide-based vaccines for the treatment of hematologic malignancies and solid tumor indications. The company is headquartered in Houston, Texas.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 6/30/2025
Next Earnings Date N/A

Stock Price History
Last Day Price 0.87
Price 4 Years Ago 9.50
Last Day Price Updated 9/4/2025 5:05:37 AM EST
Last Day Volume 546,838
Average Daily Volume 1,821,924
52-Week High 5.95
52-Week Low 0.81
Last Price to 52 Week Low 7.41%

Valuation Measures
Trailing PE N/A
Industry PE N/A
Sector PE N/A
5-Year Average PE -2.44
Free Cash Flow Ratio 1.07
Industry Free Cash Flow Ratio N/A
Sector Free Cash Flow Ratio N/A
Current Ratio Most Recent Quarter 3.45
Total Cash Per Share 0.81
Book Value Per Share Most Recent Quarter 0.93
Price to Book Ratio 1.10
Industry Price to Book Ratio N/A
Sector Price to Book Ratio N/A
Price to Sales Ratio Twelve Trailing Months 2.15
Industry Price to Sales Ratio Twelve Trailing Months N/A
Sector Price to Sales Ratio Twelve Trailing Months N/A
Analyst Buy Ratings 2
Analyst Strong Buy Ratings 0

Share Statistics
Total Shares Outstanding 12,938,900
Market Capitalization 11,256,843
Institutional Ownership 26.32%

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 3.89%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -30.28%
Reported EPS 12 Trailing Months -1.35
Reported EPS Past Year -0.71
Reported EPS Prior Year -1.24
Net Income Twelve Trailing Months -14,607,564
Net Income Past Year -10,731,000
Net Income Prior Year -8,237,000
Quarterly Revenue Growth YOY -26.30%
5-Year Revenue Growth 98.63%
Operating Margin Twelve Trailing Months -494.80%

Balance Sheet
Total Cash Most Recent Quarter 10,461,971
Total Cash Past Year 19,192,440
Total Cash Prior Year 15,111,450
Net Cash Position Most Recent Quarter 10,461,971
Net Cash Position Past Year 19,192,440
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 18,558,406
Total Stockholder Equity Prior Year 14,052,543
Total Stockholder Equity Most Recent Quarter 10,490,393

Free Cash Flow
Free Cash Flow Twelve Trailing Months -10,883,743
Free Cash Flow Per Share Twelve Trailing Months -0.84
Free Cash Flow Past Year -10,910,324
Free Cash Flow Prior Year -16,439,962

Options
Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD -0.13
MACD Signal -0.10
20-Day Bollinger Lower Band 0.86
20-Day Bollinger Middle Band 1.36
20-Day Bollinger Upper Band 1.86
Beta 1.45
RSI 33.67
50-Day SMA 3.13
150-Day SMA 0.00
200-Day SMA 3.71

System
Modified 9/4/2025 5:05:38 AM EST